Posted by Michael Wonder on 02 Sep 2020
TGA announces it has approved Yescarta
2 September 2020 - Announcement in September of a decision made in February.
On 11 February 2020, the TGA approved axicabtagene ciloleucel (Yescarta) for the treatment of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
